FR2460674A1 - Succedane du sang contenant de l'hemoglobine modifiee - Google Patents

Succedane du sang contenant de l'hemoglobine modifiee Download PDF

Info

Publication number
FR2460674A1
FR2460674A1 FR8015568A FR8015568A FR2460674A1 FR 2460674 A1 FR2460674 A1 FR 2460674A1 FR 8015568 A FR8015568 A FR 8015568A FR 8015568 A FR8015568 A FR 8015568A FR 2460674 A1 FR2460674 A1 FR 2460674A1
Authority
FR
France
Prior art keywords
hemoglobin
modified
polyethylene glycol
esleneglycol
modified hemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8015568A
Other languages
English (en)
French (fr)
Other versions
FR2460674B1 (enExample
Inventor
Yuki Iwashita
Katsumi Ajisaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of FR2460674A1 publication Critical patent/FR2460674A1/fr
Application granted granted Critical
Publication of FR2460674B1 publication Critical patent/FR2460674B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR8015568A 1979-07-11 1980-07-11 Succedane du sang contenant de l'hemoglobine modifiee Granted FR2460674A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP54087910A JPS6023084B2 (ja) 1979-07-11 1979-07-11 代用血液

Publications (2)

Publication Number Publication Date
FR2460674A1 true FR2460674A1 (fr) 1981-01-30
FR2460674B1 FR2460674B1 (enExample) 1983-06-24

Family

ID=13928063

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8015568A Granted FR2460674A1 (fr) 1979-07-11 1980-07-11 Succedane du sang contenant de l'hemoglobine modifiee

Country Status (6)

Country Link
US (1) US4301144A (enExample)
JP (1) JPS6023084B2 (enExample)
CA (1) CA1146858A (enExample)
DE (1) DE3026398A1 (enExample)
FR (1) FR2460674A1 (enExample)
GB (1) GB2055868B (enExample)

Families Citing this family (915)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS58225025A (ja) * 1982-06-24 1983-12-27 Nippon Chem Res Kk 効力持続性組成物
JPS59104323A (ja) * 1982-12-07 1984-06-16 Ajinomoto Co Inc 代用血液
DE3340592A1 (de) * 1983-11-10 1985-05-23 B. Braun Melsungen Ag, 3508 Melsungen Konjugate makromolekularer verbindungen an haemoglobine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
USRE34271E (en) * 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
JPS6153223A (ja) * 1984-08-22 1986-03-17 Ajinomoto Co Inc ヘモグロビン−ポリアルキレングリコ−ル結合体の製造方法
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) * 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5239061A (en) * 1990-06-20 1993-08-24 Research Corporation Technologies, Inc. Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
US5248766A (en) * 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
US5334705A (en) * 1991-08-15 1994-08-02 Duke University Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
EP0611306B1 (en) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5578564A (en) * 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
US5840851A (en) * 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5665869A (en) * 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
GEP20002180B (en) * 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US6306454B1 (en) * 1994-10-17 2001-10-23 Baxter International Inc. Method for producing improved medical devices and devices so produced
US5585484A (en) * 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US6083913A (en) 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5865784A (en) * 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
WO1997022371A1 (en) 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
ATE302019T1 (de) * 1997-02-28 2005-09-15 Univ California Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
IL133122A0 (en) 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU8485098A (en) * 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
CA2382409A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
JP4303883B2 (ja) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
EP1021542B1 (en) 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
DK1027437T3 (da) 1997-10-29 2008-11-24 Genentech Inc Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1
JP2001520885A (ja) 1997-10-29 2001-11-06 ジェネンテック・インコーポレーテッド Ｗｎｔ−１誘導遺伝子
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ATE410512T1 (de) 1997-11-21 2008-10-15 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
ATE443723T1 (de) * 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
MEP42108A (en) * 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1141299A2 (en) 1998-12-23 2001-10-10 Genentech, Inc. Il-1 related polypeptides
JP2000230000A (ja) * 1999-02-08 2000-08-22 Hokkaido Univ 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体
CA2266174A1 (en) * 1999-03-18 2000-09-18 Hemosol Inc. Hemoglobin-antioxidant conjugates
KR100316154B1 (ko) * 1999-03-26 2001-12-12 노광 폴리에틸렌글리콜－헤모글로빈 결합체
WO2000061746A1 (en) 1999-04-12 2000-10-19 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
EP1792989A1 (en) 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
PT1200590E (pt) 1999-08-12 2009-03-24 Agensys Inc Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
HK1048494B (en) 1999-10-05 2009-06-12 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US6180598B1 (en) 1999-10-07 2001-01-30 Deanna J. Nelson Covalently modified hemoglobin having low temperature-dependent oxygen-binding function
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
IL149340A0 (en) 1999-11-18 2002-11-10 Corvas Int Inc Nucleic acids encoding endotheliases, endotheliases and uses thereof
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
CA2491433A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
DK1897945T3 (da) 1999-12-23 2012-05-07 Genentech Inc IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US6740520B2 (en) * 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
US20040086970A1 (en) * 2000-03-22 2004-05-06 Genentech, Inc. Novel cytokine receptors and nucleic acids encoding the same
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE10031740A1 (de) 2000-06-29 2002-02-14 Sanguibio Tech Ag Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung
DE10031744A1 (de) 2000-06-29 2002-01-17 Sanguibio Tech Ag Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020115058A1 (en) * 2000-09-22 2002-08-22 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US20020164576A1 (en) * 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US6576452B1 (en) 2000-10-04 2003-06-10 Genencor International, Inc. 2,5-diketo-L-gluconic acid reductases and methods of use
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030165878A1 (en) * 2000-12-22 2003-09-04 Morris David W. Novel compositions and methods in cancer associated with altered expression of MCM3AP
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030099963A1 (en) * 2000-12-22 2003-05-29 Morris David W. Novel compositions and methods in cancer associated with altered expression of TBX21
US20030232334A1 (en) 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7645441B2 (en) * 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
PT2000545E (pt) 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
AU2002320628A1 (en) 2001-07-19 2003-03-03 Albert Einstein College Of Medecine Of Yeshiva University Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
EP2311960A3 (en) 2001-08-29 2011-06-01 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
AU2002314790A1 (en) * 2001-12-05 2003-06-23 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS OF TREATING IMMUNE-INFLAMMATORY DISEASES
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
KR100508358B1 (ko) * 2002-03-20 2005-08-17 주식회사 바이오폴리메드 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 ｇ-ｃｓｆ의 제조 방법
EP2093233A1 (en) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7452533B2 (en) * 2002-03-26 2008-11-18 Biosynexus Incorporated Antimicrobial polymer conjugate containing lysostaphin and polyethylene glycol
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2003093296A2 (en) 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP1553912A4 (en) * 2002-06-07 2007-08-08 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004011611A2 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
DE60335195D1 (de) * 2002-08-12 2011-01-13 Danisco Us Inc Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
EP1578373A4 (en) 2002-09-11 2007-10-24 Genentech Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
EP1565200A4 (en) 2002-11-27 2009-06-24 Agensys Inc NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
WO2004054473A1 (en) * 2002-12-12 2004-07-01 Baxter International Inc. Method for producing medical devices and devices so produced
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
JP5207590B2 (ja) * 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
EP1581904A2 (en) * 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
JP2007524361A (ja) 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
JP2007524362A (ja) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
US7235639B2 (en) 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP2007526220A (ja) * 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
WO2005035569A2 (en) * 2003-10-10 2005-04-21 Five Prime Therapeutics, Inc. Kiaa0779, splice variants thereof, and methods of their use
EP1675871A2 (en) 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
DK2295073T3 (da) 2003-11-17 2014-07-28 Genentech Inc Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
SI2311873T1 (sl) 2004-01-07 2018-12-31 Novartis Vaccines And Diagnostics, Inc. M-CSF-specifična monoklonska protitelesa in njihova uporaba
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
CN104174071A (zh) 2004-04-28 2014-12-03 安希奥设备国际有限责任公司 用于形成交联生物材料的组合物和系统及关联的制备方法与用途
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1796602A4 (en) 2004-09-17 2016-10-19 Angiotech Pharm Inc MULTIFUNCTIONAL COMPOUNDS FOR PRODUCING NETWORKED BIOMATERIALS AND MANUFACTURING AND USE METHOD THEREFOR
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
AU2005295640B2 (en) 2004-10-15 2011-07-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
EP1865981A2 (en) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in cancer diagnosis, detection and treatment
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
TWI299257B (en) * 2005-05-16 2008-08-01 Tung Hai Biotechnology Corp γ-POLYGLUTAMIC ACID (γ-PGA, H FORM), γ-POLYGLUTAMATES AND γ-POLYGLUTAMATE HYDROGEL FOR USE AS NUTRITION SUPPLEMENTS IN DIETARY PRODUCTS
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
EP2277916A3 (en) * 2005-07-28 2011-04-27 Novartis AG Use of antibody to M-CSF
US20070092482A1 (en) * 2005-08-04 2007-04-26 Bossard Mary J Conjugates of a G-CSF moiety and a polymer
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1922410A2 (en) 2005-08-15 2008-05-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2620903A1 (en) 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
CA2624900A1 (en) * 2005-10-04 2007-04-19 The Research Foundation Of State University Of New York Fibronectin polypeptides and methods of use
US20090155850A1 (en) * 2005-10-28 2009-06-18 The Florida International University Board Of Trustees Horse:Human Chimeric Antibodies
AU2006315037C1 (en) 2005-11-18 2013-05-02 Ichnos Sciences SA Anti-alpha2 integrin antibodies and their uses
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ES2618543T3 (es) * 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
NZ615012A (en) 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
EP2041174A2 (en) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
CA2659820A1 (en) * 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
CN101516914A (zh) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 针对ccr5的抗体及其应用
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP1914303A1 (en) * 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA polymerases
PL2087002T3 (pl) 2006-10-27 2015-02-27 Lpath Inc Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
KR20090105913A (ko) 2006-11-02 2009-10-07 다니엘 제이 카폰 이동 부분을 갖는 하이브리드 면역글로불린
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
KR20090087027A (ko) 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
CN101199856B (zh) * 2006-12-15 2011-04-20 天津协和生物科技发展有限公司 一种携氧抗休克药物
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
JP2010517944A (ja) * 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー Ｄｌｌ４シグナリング阻害薬およびその使用
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
US8415453B2 (en) * 2007-02-13 2013-04-09 Academia Sinica Lung cancer-targeted peptides and applications thereof
US8088887B2 (en) * 2007-02-13 2012-01-03 Academia Sinica Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
CN101686939B (zh) * 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
EP2160464B1 (en) 2007-05-30 2014-05-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
ES2585702T3 (es) 2007-05-30 2016-10-07 Lpath, Inc Composiciones y métodos para la unión al ácido lisofosfatídico
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2008157483A2 (en) * 2007-06-14 2008-12-24 The Research Foundation Of State University Of New York Polypeptides and methods of use
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
HRP20140315T1 (hr) 2007-07-26 2014-05-09 Amgen Inc. Modificirani enzimi lecitin-kolesterol aciltransferaze
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
TW200911289A (en) * 2007-08-09 2009-03-16 Syntonix Pharmaceuticals Inc Immunomodulatory peptides
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
RU2559782C2 (ru) 2007-12-17 2015-08-10 Марфл Аб Набор для детекции спор, происходящих из микобактерий
EP2235058A2 (en) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
EP2238170B1 (en) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
US8921315B1 (en) 2008-04-24 2014-12-30 Neumedicines, Inc. Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US7833530B2 (en) 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
JP2011526916A (ja) * 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
NZ591488A (en) 2008-09-07 2012-11-30 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
NO2344540T3 (enExample) 2008-10-02 2018-04-28
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック， インコーポレイテッド 軸索変性の調節
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010052556A1 (en) * 2008-11-06 2010-05-14 Glenmark Pharmaceuticals S.A. Treatment with anti-alpha2 integrin antibodies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
EP2365803B1 (en) 2008-11-24 2017-11-01 Northwestern University Polyvalent rna-nanoparticle compositions
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100294952A1 (en) * 2009-01-15 2010-11-25 Northwestern University Controlled agent release and sequestration
EP3002296B1 (en) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA33248B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Traitement de troubles résistant à l'insuline
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
AP2011005956A0 (en) * 2009-04-20 2011-10-31 Gilead Calistoga Llc Methods of treatment for solid tumors.
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
MX2011013903A (es) 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
KR20120097481A (ko) * 2009-07-20 2012-09-04 내셔날 쳉쿵 유니버시티 사람 혈청 알부민(ＨＳＡ)의 변이체와 컨쥬게이션된 αｖβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
NZ597531A (en) 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011045704A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
KR101952453B1 (ko) * 2009-10-15 2019-02-26 제넨테크, 인크. 수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
EP3011970A3 (en) 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation of axon degeneration
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
US20110110942A1 (en) 2009-11-12 2011-05-12 Genentech, Inc. Method of promoting dendritic spine density
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
US20120231006A1 (en) 2009-11-20 2012-09-13 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
WO2011066511A1 (en) 2009-11-30 2011-06-03 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
PH12012500982A1 (en) 2009-11-30 2019-07-10 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US20120288507A1 (en) 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
NZ600544A (en) 2009-12-23 2014-06-27 Univ Nat Cheng Kung Compositions and methods for the treatment of angiogenesis-related eye diseases
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
KR20130020765A (ko) 2010-02-16 2013-02-28 메디뮨 엘엘씨 Ｈｓａ-관련 조성물 및 사용방법
CA2790866C (en) 2010-02-23 2019-02-12 Sanofi Anti-alpha2 integrin antibodies and their uses
MA34057B1 (fr) 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
CN102859364A (zh) 2010-02-25 2013-01-02 桑格特公司 通过减少反应物比例制备聚乙二醇-血红蛋白缀合物的方法
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
HUE049849T2 (hu) 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
DK2552443T3 (da) 2010-04-01 2021-09-27 Oncorena Ab Forbedret behandling af nyrecellekarcinom
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US9878012B2 (en) 2010-05-18 2018-01-30 Neumedicines, Inc. IL-12 formulations for enhancing hematopoiesis
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
CA2802994A1 (en) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions and methods for treating inflammatory conditions
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9040671B2 (en) 2010-07-23 2015-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for cancer management targeting Co-029
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
CN105198981B (zh) 2010-08-20 2019-07-16 惠氏有限责任公司 经设计的成骨蛋白
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9445990B2 (en) 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
EP2654781B1 (en) 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
EP2678358B1 (en) 2011-02-23 2015-07-22 F.Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
EP3147297B1 (en) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
PH12013502240B1 (en) 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN108892709A (zh) 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
DK2710031T3 (en) 2011-05-18 2018-01-02 Mederis Diabetes Llc IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
JP2014516960A (ja) 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
WO2012174056A1 (en) 2011-06-13 2012-12-20 Neumedicines, Inc. Mitigation of cutaneous injury with il-12
WO2012178063A1 (en) 2011-06-23 2012-12-27 The Regents Of The University Of Michigan Compound and method for modulating opioid receptor activity
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013025479A1 (en) 2011-08-16 2013-02-21 Emory University Jaml specific binding agents, antibodies, and uses related thereto
KR20140068877A (ko) 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SI3536710T1 (sl) 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
BR112014012590A8 (pt) 2011-11-23 2017-12-19 Igenica Inc Anticorpos anti-cd98 e métodos de uso dos mesmos
HK1202433A1 (en) 2011-12-16 2015-10-02 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
JP2015505326A (ja) 2012-01-18 2015-02-19 ニューメディシンズ，インコーポレーテッド 放射線防護及び放射線誘発性毒性緩和のためのｉｌ−１２
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
NZ629684A (en) 2012-03-05 2016-10-28 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
CA2867444C (en) 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2868883C (en) 2012-03-30 2022-10-04 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013155346A1 (en) 2012-04-11 2013-10-17 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
NZ703724A (en) 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
CN105050618B (zh) 2012-06-21 2018-11-16 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
WO2013192596A2 (en) 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
EP3431497B1 (en) 2012-06-27 2022-07-27 The Trustees of Princeton University Split inteins, conjugates and uses thereof
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
EP2879710B1 (en) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Medical uses of agents that modulate immune cell activation and corresponding screening methods
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
EP3738605A1 (en) 2012-09-10 2020-11-18 Xencor, Inc. Methods of treating neurological diseases
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
MX360816B (es) 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
ES2906975T3 (es) 2012-11-20 2022-04-21 Eumederis Pharmaceuticals Inc Productos farmacéuticos de péptidos mejorados
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
HK1210713A1 (en) 2012-12-27 2016-05-06 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2951206A2 (en) 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
PL2970449T3 (pl) 2013-03-15 2020-04-30 Amgen Research (Munich) Gmbh Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2924386C (en) 2013-10-04 2021-07-20 F. Hoffmann-La Roche Ag Antibodies specifically binding to her3
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
WO2015057583A1 (en) 2013-10-14 2015-04-23 The United States Of America, As Represented By The Secretary Treatment of chronic kidney disease with sahps
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
EP3063317B1 (en) 2013-10-28 2020-06-03 DOTS Technology Corp. Allergen detection
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
AU2015204446A1 (en) 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
WO2015127134A2 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
CN110724691A (zh) 2014-02-27 2020-01-24 阿勒根公司 补体因子Bb抗体
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
KR102587838B1 (ko) 2014-03-14 2023-10-12 바이오몰레큘러 홀딩스 엘엘씨 비-펩티드 결합을 함유하는 하이브리드 면역글로불린
EP3699195A3 (en) 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
PT3155017T (pt) 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina
EP3613433B1 (en) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Anti-epidermal growth factor receptor (egfr) antibodies
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
MX384418B (es) 2014-07-31 2025-03-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
EA201790437A1 (ru) 2014-08-22 2017-08-31 Сорренто Терапьютикс, Инк. Антигенсвязывающие белки, связывающиеся с cxcr3
MX382490B (es) 2014-08-27 2025-03-13 Amgen Inc Variantes de inhibidor de tejido de metaloproteinasa tipo tres (timp-3), composiciones y metodos
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
KR20230128139A (ko) 2014-10-24 2023-09-01 아스트라제네카 아베 조합물
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
CN111018987B (zh) 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
ES3015000T3 (en) 2014-12-08 2025-04-28 Dana Farber Cancer Inst Inc Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
AU2016215535B2 (en) 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
US10266584B2 (en) 2015-02-09 2019-04-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
EP3256165B1 (en) 2015-02-13 2021-07-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US9951144B2 (en) 2015-04-08 2018-04-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
CN107750255B (zh) 2015-04-17 2022-08-30 安进研发（慕尼黑）股份有限公司 用于cdh3和cd3的双特异性抗体构建体
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US10519207B2 (en) 2015-06-12 2019-12-31 Georgia State University Research Foundation, Inc. Compositions and methods for treating opioid tolerance
CA2992660A1 (en) 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3334762A1 (en) 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
CN107922501A (zh) 2015-09-01 2018-04-17 勃林格殷格翰国际有限公司 抗cd40抗体用于治疗狼疮性肾炎的用途
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
US20180280474A1 (en) 2015-10-01 2018-10-04 Amgen Inc. Treatment of bile acid disorders
EP3359575B1 (en) 2015-10-09 2020-07-22 Florida State University Research Foundation, Inc. Antibodies specific for 4,6-diamino-5-(formylamino) pyrimidine and uses thereof
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN109069871A (zh) 2015-12-04 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的新抗体
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
WO2017132562A1 (en) 2016-01-29 2017-08-03 Heyue Zhou Antigen binding proteins that bind pd-l1
EA201891753A1 (ru) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
CN109071669A (zh) 2016-03-07 2018-12-21 查尔斯顿制药有限责任公司 抗核仁素抗体
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3035561A1 (en) 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
CA3037144A1 (en) 2016-09-16 2018-03-22 Shanghai Henlius Biotech, Inc. Anti-pd-1 antibodies
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
WO2018067754A1 (en) 2016-10-04 2018-04-12 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
IL266023B2 (en) 2016-10-14 2024-07-01 Neomatrix Therapeutics Inc Peptides Derived from Fibronectin with Improved Bioactivity and Reduced Susceptibility to Neutrophil Elastase Degradation for Use in Treating Wounds
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
AU2017332960B2 (en) 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
US10960070B2 (en) 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
JP7136468B2 (ja) 2016-11-08 2022-09-13 ユニバーシティ オブ マイアミ 抗セクレトグラニンｉｉｉ（ｓｃｇ３）抗体およびその使用
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
TW202130652A (zh) 2017-01-19 2021-08-16 美國衛生與公眾服務部 Apoc-ii擬肽
SMT202500367T1 (it) 2017-02-02 2025-11-10 Amgen Res Munich Gmbh Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
UY37726A (es) 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
CA3102086A1 (en) 2017-06-06 2018-12-13 Relinia, Inc. Single-chain tnf receptor 2 agonist fusion proteins
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
EP4424366A3 (en) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
KR102788331B1 (ko) 2017-07-07 2025-03-27 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
WO2019070086A2 (en) * 2017-09-20 2019-04-11 RIM, Chang Ho BLOOD SUBSTITUTE CARRYING OXYGEN OBTAINED FROM PORK BLOOD AND METHOD OF MAKING SAME
AU2018361819B2 (en) 2017-11-02 2025-01-09 Oxford Biotherapeutics Ltd Antibodies and methods of use
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
RS67119B1 (sr) 2017-11-14 2025-09-30 Arcellx Inc Polipeptidi koji obuhvataju d domen i njihove upotrebe
AU2018383679B2 (en) 2017-12-11 2025-10-09 Amgen Inc. Continuous manufacturing process for bispecific antibody products
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
JP7490565B2 (ja) 2017-12-29 2024-05-27 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
EP4506017A3 (en) 2018-01-03 2025-05-14 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
CR20200327A (es) 2018-01-26 2020-11-05 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
CN112020365A (zh) 2018-01-26 2020-12-01 豪夫迈·罗氏有限公司 组合物和使用方法
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
KR20250139415A (ko) 2018-02-14 2025-09-23 호라이즌 테라퓨틱스 아일랜드 디에이씨 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
KR20200123118A (ko) 2018-02-21 2020-10-28 제넨테크, 인크. IL-22 Fc 융합 단백질로 치료를 위한 투약
WO2019168897A2 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
EP3765522A4 (en) 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
IL277464B1 (en) 2018-03-21 2026-04-01 Baxalta Inc Separation of VWF and VWF propeptide using chromatographic methods
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP7429192B2 (ja) 2018-04-06 2024-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
EP3774916A2 (en) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
KR20210005097A (ko) 2018-04-30 2021-01-13 메디뮨 리미티드 응집체를 표적화하고 제거하는 접합체
WO2019211665A1 (en) 2018-04-30 2019-11-07 Takeda Pharmaceutical Company Limited Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗ｓｉｒｐａ抗体およびその使用法
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN110655577A (zh) 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
DK3807316T3 (da) 2018-06-18 2024-07-29 Innate Pharma Sammensætninger og fremgangsmåder til behandling af cancer
EP3806889A4 (en) 2018-06-18 2022-07-13 Anwita Biosciences, Inc. CYTOKI FUSION PROTEINS AND USES THEREOF
KR20250156190A (ko) 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
BR112020026819A2 (pt) 2018-06-29 2021-04-20 Alector Llc anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
WO2020006347A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
TW202519260A (zh) 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
CA3107186A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
WO2020025792A1 (en) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
US20210347848A1 (en) 2018-08-31 2021-11-11 ALX Oncology Inc. Decoy polypeptides
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
CN113365697B (zh) 2018-09-25 2024-07-19 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
JP7644706B2 (ja) 2018-10-11 2025-03-12 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
JP2022513082A (ja) 2018-11-19 2022-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
WO2020142740A1 (en) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
WO2020161214A1 (en) 2019-02-07 2020-08-13 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
AU2020227824B2 (en) 2019-02-27 2025-07-10 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
WO2020191365A1 (en) 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
CN114096559B (zh) 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
AU2020272939A1 (en) 2019-04-09 2021-11-11 Abcuro, Inc. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies
EP3962529A4 (en) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
CN113728003A (zh) 2019-04-30 2021-11-30 吉加根公司 重组多克隆蛋白及其使用方法
WO2020225400A1 (en) 2019-05-09 2020-11-12 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating eye or ocular diseases
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
AU2020298833A1 (en) 2019-07-03 2022-01-20 Oxford Biotherapeutics Ltd Antibodies and methods of use
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CA3145885A1 (en) 2019-07-31 2021-02-04 Jeonghoon Sun Anti-ms4a4a antibodies and methods of use thereof
WO2021023624A1 (en) 2019-08-02 2021-02-11 Orega Biotech Novel il-17b antibodies
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
PH12022550326A1 (en) 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
CN114929260A (zh) 2019-09-11 2022-08-19 武田药品工业株式会社 与冯维勒布兰德因子和补体c1q的复合物相关的治疗方法
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
WO2021091885A2 (en) 2019-11-04 2021-05-14 Alector Llc Siglec-9 ecd fusion molecules and methods of use thereof
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
AU2020397416A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis B infection
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US20210221886A1 (en) 2019-12-05 2021-07-22 Sorrento Therapeutics, Inc. Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
MX2022007231A (es) 2019-12-13 2022-07-12 Alector Llc Anticuerpos anti-mertk y metodos de uso de los mismos.
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 / tnf receptor agonist for use in medicine
CA3162011A1 (en) 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
EP4090365A1 (en) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
WO2021146383A1 (en) 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
EP4093513A4 (en) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
CN115335074A (zh) 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
CA3168986A1 (en) 2020-02-26 2021-09-02 Sorrento Therapeutics, Inc. Activatable antigen binding proteins with universal masking moieties
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
CN116075525A (zh) 2020-03-31 2023-05-05 艾莱克特有限责任公司 抗mertk抗体及其使用方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
JP7713956B2 (ja) 2020-04-15 2025-07-28 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20240209085A1 (en) 2020-05-29 2024-06-27 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
CN116670285A (zh) 2020-06-23 2023-08-29 江苏康缘药业股份有限公司 抗cd38抗体及其用途
US20230235059A1 (en) 2020-06-26 2023-07-27 Sorrento Therapeutics, Inc. Anti-pd1 antibodies and uses thereof
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
JP2023537470A (ja) 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
AU2021335257A1 (en) 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
EP4213939A1 (en) 2020-09-21 2023-07-26 Boehringer Ingelheim International GmbH Use of anti-cd40 antibodies for treatment of inflammatory conditions
US20230381293A1 (en) 2020-10-14 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Stabilized norovirus virus-like particles as vaccine immunogens
US20220127344A1 (en) 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
CR20230229A (es) 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
UY39507A (es) 2020-11-06 2022-03-31 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
WO2022096704A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
TW202225188A (zh) 2020-11-06 2022-07-01 德商安美基研究（慕尼黑）公司 與ｃｄ３結合的多肽構建體
AU2021379882A1 (en) 2020-11-10 2023-06-29 Sanofi Ceacam5 antibody-drug conjugate formulation
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CN117043183A (zh) 2020-12-16 2023-11-10 沃雅戈治疗公司 Tau结合化合物
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
US20250282870A1 (en) 2021-01-20 2025-09-11 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
EP4284828A1 (en) 2021-01-28 2023-12-06 Talem Therapeutics LLC Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
CN117062836A (zh) 2021-02-05 2023-11-14 勃林格殷格翰国际有限公司 抗il1rap抗体
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
CA3212311A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
CN115141276A (zh) 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
US20250282887A1 (en) 2021-04-02 2025-09-11 Amgen Inc. Mageb2 binding constructs
JP2024518369A (ja) 2021-05-06 2024-05-01 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング 増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
TW202317620A (zh) 2021-06-04 2023-05-01 德商百靈佳殷格翰國際股份有限公司 抗ＳＩＲＰα抗體
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
EP4351732A1 (en) 2021-06-09 2024-04-17 Evotec International GmbH Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2023009498A1 (en) 2021-07-26 2023-02-02 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
AU2022402334A1 (en) 2021-12-02 2024-07-18 Sanofi Ceacam5 adc–anti-pd1/pd-l1 combination therapy
EP4440603A1 (en) 2021-12-02 2024-10-09 Sanofi Cea assay for patient selection in cancer therapy
CR20240265A (es) 2021-12-22 2024-10-16 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
US20250179210A1 (en) 2022-03-09 2025-06-05 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
WO2023194333A1 (en) 2022-04-04 2023-10-12 Swiftpharma Bv Recombinant spider silk-reinforced collagen proteins produced in plants and the use thereof
EP4522651A1 (en) 2022-05-12 2025-03-19 Amgen Research (Munich) GmbH Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
JP2025525530A (ja) 2022-07-15 2025-08-05 ヤンセン バイオテツク，インコーポレーテツド 抗原結合可変領域の改善された生物工学による対合のための材料及び方法
EP4558523A1 (en) 2022-07-19 2025-05-28 Biolegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
MA71628A (fr) 2022-07-29 2025-05-30 Alector Llc Anticorps anti-gpnmb et leurs méthodes d'utilisation
CN119968395A (zh) 2022-08-18 2025-05-09 百进生物科技公司 抗axl抗体、其抗原结合片段及其制备和使用方法
CN119744271A (zh) 2022-09-08 2025-04-01 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
EP4615480A1 (en) 2022-11-07 2025-09-17 Alector LLC Uses of siglec-9 ecd fusion molecules in cancer treatment
EP4619045A1 (en) 2022-11-17 2025-09-24 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
CN121127494A (zh) 2023-01-06 2025-12-12 武田药品工业株式会社 用于治疗自身免疫性疾病的抗cd38抗体
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
CN121712787A (zh) 2023-06-14 2026-03-20 马里亚纳肿瘤学公司 靶向dll3的肽及其构建体
KR20260026051A (ko) 2023-06-14 2026-02-25 마리아나 온콜로지 인크. Dll3 표적화 펩티드 및 이의 구성체
CN121712788A (zh) 2023-06-14 2026-03-20 马里亚纳肿瘤学公司 靶向dll3的肽及其构建体
UY40797A (es) 2023-06-14 2024-12-31 Amgen Inc Moléculas captadoras de enmascaramiento de células t
CN121358777A (zh) 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
WO2025038732A1 (en) 2023-08-15 2025-02-20 Gigagen, Inc. Recombinant polyclonal proteins targeting hepatitis b virus (hbv) and methods of use thereof
CN121816366A (zh) 2023-09-27 2026-04-07 百进公司 抗gpc4抗体
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules
WO2025074337A1 (en) 2023-10-06 2025-04-10 Boehringer Ingelheim International Gmbh Use of anti-sirp-alpha antibodies to treat a liver disease or disorder
WO2025074328A1 (en) 2023-10-06 2025-04-10 Boehringer Ingelheim International Gmbh Use of anti-sirp-alpha antibodies to treat cancer
WO2025117586A1 (en) 2023-11-27 2025-06-05 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
WO2025122615A1 (en) 2023-12-05 2025-06-12 Mariana Oncology Inc. Enriched and stable radioligand therapy formulations and pharmaceutical compositions comprising same
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025155843A1 (en) 2024-01-19 2025-07-24 Akero Therapeutics, Inc. Method of treating liver or lung injury
TW202600175A (zh) 2024-02-15 2026-01-01 德商馬克專利公司 用於治療gd2陽性癌症之抗gd2抗體及免疫結合物
WO2025181215A1 (en) 2024-03-01 2025-09-04 Boehringer Ingelheim International Gmbh Antibodies to connective tissue growth factor (ctgf) and uses thereof
WO2025193746A1 (en) 2024-03-12 2025-09-18 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof
WO2025210264A1 (en) 2024-04-04 2025-10-09 Merck Patent Gmbh Antibody-drug-conjugates binding napi2b
WO2025235919A1 (en) 2024-05-09 2025-11-13 Takeda Pharmaceutical Company Limited Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2025254987A1 (en) 2024-06-03 2025-12-11 Alector Llc Siglec-9 ecd fusion molecule variants and methods of use thereof
WO2026024904A1 (en) 2024-07-24 2026-01-29 Gigagen, Inc. Custom recombinant polyclonal proteins and methods of use thereof
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders
WO2026072990A1 (en) 2024-09-27 2026-04-02 Abcuro, Inc. Methods of treating t-cell large granular lymphocytic leukemia
WO2026082894A1 (en) 2024-10-17 2026-04-23 Sanofi Ceacam5 antibody-drug conjugate for use in cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2328478A1 (fr) * 1975-10-22 1977-05-20 Wong Jeffrey Substitut du sang a base d'hemoglobine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2328478A1 (fr) * 1975-10-22 1977-05-20 Wong Jeffrey Substitut du sang a base d'hemoglobine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXBK/81 *

Also Published As

Publication number Publication date
JPS6023084B2 (ja) 1985-06-05
GB2055868B (en) 1983-04-07
GB2055868A (en) 1981-03-11
US4301144A (en) 1981-11-17
FR2460674B1 (enExample) 1983-06-24
JPS5612308A (en) 1981-02-06
CA1146858A (en) 1983-05-24
DE3026398C2 (enExample) 1990-09-13
DE3026398A1 (de) 1981-03-26

Similar Documents

Publication Publication Date Title
FR2460674A1 (fr) Succedane du sang contenant de l'hemoglobine modifiee
EP1066016B1 (fr) Derives de polyamino-acides et leur utilisation dans des compositions de traitement des fibres keratiniques
FR2600255A1 (fr) Substituant acellulaire des hematies
FR2509175A1 (fr) Preparation therapeutique ayant d'excellentes proprietes d'absorption
FR2512669A1 (fr) Composition pour traitement capillaire
CA1209127A (fr) Derive proteinique comportant en greffage, des restes absorbeurs d'ultra-violets, son procede de preparation et compositions le contenant
US20090137762A1 (en) Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
FR2653334A1 (fr) Preparation cosmetique de bronzage.
JP2978187B2 (ja) 修飾スーパーオキサイドディスムターゼの製造法
EP0601911B1 (fr) Acylaminoacides obtenus par l'acylation d'hydrolysats de protéines et compositions anti-microbiennes, antiparasitaires ou cosmétiques en contenant
EP1440092A2 (fr) Composition photoactivable et utilisations
BE1004915A3 (fr) Collagene, procede pour le preparer, et agent cosmetique le contenant.
CA2089853C (fr) Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses
CH634041A5 (fr) Derives de la pepstatine, leur preparation et composition les contenant.
US6956025B2 (en) Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof
FR2512030A1 (fr) Procede de preparation d'elastine soluble partiellement hydrolysee et son hydrolysat
CN87104249A (zh) 超氧化物歧化酶衍生物制备方法及医学上的应用
WO2007081209A1 (en) Uv-absorbing polymers consisting of gelatin and aminobutadiene
FR2574662A1 (fr) Procede de preparation d'un nouveau complexe d'hemine et produit ainsi obtenu et medicaments le contenant
EP1362851B1 (fr) Composés diazirine-actifs photo-activables, compositions les contenant et leurs utilisations
AU782407B2 (en) Hemoglobin-antioxidant conjugates
MC1099A1 (fr) Médicament à base d'un polypeptide
BE897546A (fr) Nouveaux polypeptides leur preparation et leur application comme medicaments
WO2005041898A2 (en) Blood substitutes
CA2173815C (fr) Utilisation d'un compose hydrofluorocarbone dans une emulsion, emulsion et composition comprenant un tel compose